@phdthesis{Friedrich2019,
  author    = {Friedrich, Maximilian Uwe},
  title     = {Funktionelle Charakterisierung einer Tripletdeletion in SLC5A4 (SGLT3) als Kandidatengen f{\"u}r das Aufmerksamkeitsdefizit-/ Hyperaktivit{\"a}tssyndrom (ADHS)},
  doi       = {10.25972/OPUS-18479},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-184791},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2019},
  abstract  = {Natrium-Glukose Transporter (SGLT) geh{\"o}ren zur „solute carrier 5" (SLC5) Familie, die sich durch einen sekund{\"a}r aktiven, natriumabh{\"a}ngigen Transport von Zuckern und an-deren Molek{\"u}len nach intrazellul{\"a}r auszeichnen. Die durch das Gen SLC5A4 kodierte Isoform SGLT3 transportiert dagegen keinen Zucker, sondern verh{\"a}lt sich als Glukosesensor, der nach Bindung seiner Liganden eine Membrandepolarisation induziert. In genomweiten Exomsequenzierungsstudien (whole exome sequencing, WES) mehrerer erweiterter Stammb{\"a}ume mit hoher Pr{\"a}valenz des Aufmerksamkeitsdefizit-/Hyperaktivit{\"a}tssyndroms (ADHS) wurde im Vorfeld eine ATG-Tripletdeletion in SLC5A4 identifiziert, die zum Verlust einer Aminos{\"a}ure (ΔM500) in SGLT3 f{\"u}hrt und zumindest partiell mit dem klinischen Ph{\"a}notyp kosegregiert. In der vorliegenden Arbeit wurde die zentralnerv{\"o}se Expression von SGLT3 auf RNA- Ebene mittels Reverse-Transkriptase PCR sowie real-time PCR aus humanen Gesamt-RNAs nachgewiesen. Dabei konnte eine ubiquit{\"a}re Expression im Gehirn mit relativ erh{\"o}hter Expression unter anderem in Striatum und Hypothalamus, deren Dysfunktion in der Pathogenese des ADHS impliziert wurde, gezeigt werden. Da Mutationen in homologen Dom{\"a}nen der eng strukturverwandten Isoformen SGLT1 und SGLT2 sowohl intestinale als auch renale Funktionen schwer beeintr{\"a}chtigen, wurden in dieser Arbeit funktionelle Charakteristika sowohl des wildtypischen als auch der ΔM500 und der benachbarten ΔI501 Deletionsvariante von SGLT3 mittels Zwei-Elektroden Spannungs- und Stromklemme in entsprechend cRNA-injizierten Xenopus laevis Oozyten untersucht. Der hochpotente SGLT3-spezifische Iminozuckeragonist 1-Desoxynojirimycin (DNJ) induzierte an SGLT3-exprimierenden Oozyten in sauren Bedingungen etwa dreifach gr{\"o}ßere Kationeneinstr{\"o}me als D-Glukose, was sowohl im Spannungsklemmen-, und anhand einer entsprechenden Membrandepolarisation im Stromklemmenmodus gezeigt wurde. Die mit der ΔM500 bzw. ΔI501 Variante injizierten Oozyten dagegen zeigten in den maximalen Aktivierungsbedingungen um 92\% bzw. 96\% (p<0,01) reduzierte Kationeneinstr{\"o}me, sodass diese als hochgradig sch{\"a}dliche „Loss of Function" Mutationen in SGLT3 charakterisiert wurden. Dieser Befund wurde mittels bioinformatischer in-silico Effektvorhersage validiert. Um Konsequenzen der Sequenzalteration auf den Membraneinbau der Transporter zu untersuchen, wurden die mit einem gelb fluoreszierenden Farbstoff (YFP) markierten Transporter in Oozytenmembranen mittels Laser-Scanning Mikroskop nachgewiesen und die jeweiligen Mengen der Konstrukte anhand der Fluoreszenzintensit{\"a}ten quantifiziert. Dabei zeigte sich eine um 53\% bzw. 42\% (p<0,01) reduzierte Menge der mutierten Konstrukte ΔM500 bzw. ΔI501 in der Membran, was zus{\"a}tzliche sch{\"a}dliche Effekte der Mutationen auf das sogenannte Membrantargeting der Transporter belegt. Zusammenfassend demonstrieren die Ergebnisse dieser Arbeit, dass die ΔM500 Variante von SGLT3, welcher in ADHS-relevanten Hirnarealen exprimiert wird, dessen sub-stratinduzierte Natriumleitf{\"a}higkeit aufhebt und den Membraneinbau beeintr{\"a}chtigen k{\"o}nnte, was in Wechselwirkung mit anderen genetischen ADHS Risikovarianten das Risiko f{\"u}r ADHS in Mutationstr{\"a}gern beeinflussen kann.},
  subject      = {ADHS},
  language  = {de}
}
@article{HopfnerSchormairKnaufetal.2011,
  author    = {Hopfner, Franziska and Schormair, Barbara and Knauf, Franziska and Berthele, Achim and T{\"o}lle, Thomas R. and Baron, Ralf and Maier, Christoph and Treede, Rolf-Detlef and Binder, Andreas and Sommer, Claudia and Maih{\"o}fner, Christian and Kunz, Wolfram and Zimprich, Friedrich and Heemann, Uwe and Pfeufer, Arne and N{\"a}bauer, Michael and K{\"a}{\"a}b, Stefan and Nowak, Barbara and Gieger, Christian and Lichtner, Peter and Trenkwalder, Claudia and Oexle, Konrad and Winkelmann, Juliane},
  title     = {Novel SCARB2 mutation in Action Myoclonus-Renal Failure syndrome and evaluation of SCARB2 mutations in isolated AMRF features},
  series = {BMC Neurology},
  volume    = {11},
  journal   = {BMC Neurology},
  number    = {134},
  doi       = {10.1186/1471-2377-11-134},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-141209},
  pages     = {1-8},
  year      = {2011},
  abstract  = {Background: Action myoclonus-renal failure syndrome is a hereditary form of progressive myoclonus epilepsy associated with renal failure. It is considered to be an autosomal-recessive disease related to loss-of-function mutations in SCARB2. We studied a German AMRF family, additionally showing signs of demyelinating polyneuropathy and dilated cardiomyopathy. To test the hypothesis whether isolated appearance of individual AMRF syndrome features could be related to heterozygote SCARB2 mutations, we screened for SCARB2 mutations in unrelated patients showing isolated AMRF features. Methods: In the AMRF family all exons of SCARB2 were analyzed by Sanger sequencing. The mutation screening of unrelated patients with isolated AMRF features affected by either epilepsy (n = 103, progressive myoclonus epilepsy or generalized epilepsy), demyelinating polyneuropathy (n = 103), renal failure (n = 192) or dilated cardiomyopathy (n = 85) was performed as high resolution melting curve analysis of the SCARB2 exons. Results: A novel homozygous 1 bp deletion (c.111delC) in SCARB2 was found by sequencing three affected homozygous siblings of the affected family. A heterozygous sister showed generalized seizures and reduction of nerve conduction velocity in her legs. No mutations were found in the epilepsy, renal failure or dilated cardiomyopathy samples. In the polyneuropathy sample two individuals with demyelinating disease were found to be carriers of a SCARB2 frameshift mutation (c.666delCCTTA). Conclusions: Our findings indicate that demyelinating polyneuropathy and dilated cardiomyopathy are part of the action myoclonus-renal failure syndrome. Moreover, they raise the possibility that in rare cases heterozygous SCARB2 mutations may be associated with PNP features.},
  language  = {en}
}
@article{WiegeringPfannUtheetal.2013,
  author    = {Wiegering, Armin and Pfann, Christina and Uthe, Friedrich Wilhelm and Otto, Christoph and Rycak, Lukas and M{\"a}der, Uwe and Gasser, Martin and Waaga-Gasser, Anna-Maria and Eilers, Martin and Germer, Christoph-Thomas},
  title     = {CIP2A Influences Survival in Colon Cancer and Is Critical for Maintaining Myc Expression},
  series = {PLoS ONE},
  journal   = {PLoS ONE},
  doi       = {10.1371/journal.pone.0075292},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-97252},
  year      = {2013},
  abstract  = {The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncogenic factor that stabilises the c-Myc protein. CIP2A is overexpressed in several tumours, and expression levels are an independent marker for long-term outcome. To determine whether CIP2A expression is elevated in colon cancer and whether it might serve as a prognostic marker for survival, we analysed CIP2A mRNA expression by real-time PCR in 104 colon cancer samples. CIP2A mRNA was overexpressed in colon cancer samples and CIP2A expression levels correlated significantly with tumour stage. We found that CIP2A serves as an independent prognostic marker for disease-free and overall survival. Further, we investigated CIP2A-dependent effects on levels of c-Myc, Akt and on cell proliferation in three colon cancer cell lines by silencing CIP2A using small interfering (si) and short hairpin (sh) RNAs. Depletion of CIP2A substantially inhibited growth of colon cell lines and reduced c-Myc levels without affecting expression or function of the upstream regulatory kinase, Akt. Expression of CIP2A was found to be dependent on MAPK activity, linking elevated c-Myc expression to deregulated signal transduction in colon cancer.},
  language  = {en}
}
@phdthesis{Friedrich2000,
  author    = {Friedrich, Uwe},
  title     = {Elektroporation von S{\"a}ugerzellen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-1241},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2000},
  abstract  = {Ziel der Arbeit war es, die wissenschaftlichen und technischen Voraussetzungen zu schaffen, um eine effiziente Elektroporation von großen aber auch kleinen Zellzahlen zu erreichen. Ein großer Teil der Arbeit diente der Entwicklung eines neuen Elektroporationsger{\"a}tes, des Multiporators. Die synergetischen Effekte dieser Technik tragen dazu bei, dass sehr hohe Ausbeuten bei der Elektrotransfektion von Zellen erzielt werden. Damit konnte zum ersten Mal der Gentransfer durch k{\"u}nstliche S{\"a}ugerzell-Chromosomen (MACs) nachgewiesen werden. Eine weitere Anwendung der Elektroporation liegt in der Transfektion von prim{\"a}ren Zellen. Dabei ist der entscheidende Punkt f{\"u}r eine hohe Transfektionseffizienz der Zellzyklus. Des Weiteren wurde in dieser Arbeit ein Konzept entwickelt, das als Basis f{\"u}r ein neues Elektroporationssystem benutzt werden kann.},
  subject      = {S{\"a}ugetiere},
  language  = {de}
}
@article{EsserMehnert‐TheuerkaufFriedrichetal.2020,
  author    = {Esser, Peter and Mehnert-Theuerkauf, Anja and Friedrich, Michael and Johansen, Christoffer and Br{\"a}hler, Elmar and Faller, Hermann and H{\"a}rter, Martin and Koch, Uwe and Schulz, Holger and Wegscheider, Karl and Weis, Joachim and Kuba, Katharina and Hinz, Andreas and Hartung, Tim},
  title     = {Risk and associated factors of depression and anxiety in men with prostate cancer: Results from a German multicenter study},
  series = {Psycho-Oncology},
  volume    = {29},
  journal   = {Psycho-Oncology},
  number    = {10},
  doi       = {10.1002/pon.5471},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-218277},
  pages     = {1604 -- 1612},
  year      = {2020},
  abstract  = {Objective In order to optimize psycho-oncological care, studies that quantify the extent of distress and identify certain risk groups are needed. Among patients with prostate cancer (PCa), findings on depression and anxiety are limited. Methods We analyzed data of PCa patients selected from a German multi-center study. Depression and anxiety were assessed with the PHQ-9 and the GAD-7 (cut-off ≥7). We provided physical symptom burden, calculated absolute and relative risk (AR and RR) of depression and anxiety across patient subsets and between patients and the general population (GP) and tested age as a moderator within the relationship of disease-specific symptoms with depression and anxiety. Results Among 636 participants, the majority reported disease-specific problems (sexuality: 60\%; urination: 52\%). AR for depression and anxiety was 23\% and 22\%, respectively. Significant RR were small, with higher risks of distress in patients who are younger (eg, RR\(_{depression}\) = 1.15; 95\%-CI: 1.06-1.26), treated with chemotherapy (RR\(_{depression}\)n = 1.46; 95\%-CI: 1.09-1.96) or having metastases (RR\(_{depression}\) = 1.30; 95\%-CI: 1.02-1.65). Risk of distress was slightly elevated compared to GP (eg, RR\(_{depression}\) = 1.13; 95\%-CI: 1.07-1.19). Age moderated the relationship between symptoms and anxiety (B\(_{urination}\) = -0.10, P = .02; B\(_{sexuality}\) = -0.11, P = .01). Conclusions Younger patients, those with metastases or treatment with chemotherapy seem to be at elevated risk for distress and should be closely monitored. Many patients suffer from disease-specific symptom burden, by which younger patients seem to be particularly distressed. Support of coping mechanisms associated with disease-specific symptom burden seems warranted.},
  language  = {en}
}
@article{EckardtStasikKrameretal.2021,
  author    = {Eckardt, Jan-Niklas and Stasik, Sebastian and Kramer, Michael and R{\"o}llig, Christoph and Kr{\"a}mer, Alwin and Scholl, Sebastian and Hochhaus, Andreas and Crysandt, Martina and Br{\"u}mmendorf, Tim H. and Naumann, Ralph and Steffen, Bj{\"o}rn and Kunzmann, Volker and Einsele, Hermann and Schaich, Markus and Burchert, Andreas and Neubauer, Andreas and Sch{\"a}fer-Eckart, Kerstin and Schliemann, Christoph and Krause, Stefan W. and Herbst, Regina and H{\"a}nel, Mathias and Frickhofen, Norbert and Noppeney, Richard and Kaiser, Ulrich and Baldus, Claudia D. and Kaufmann, Martin and R{\´a}cil, Zdenek and Platzbecker, Uwe and Berdel, Wolfgang E. and Mayer, Jiř{\´i} and Serve, Hubert and M{\"u}ller-Tidow, Carsten and Ehninger, Gerhard and St{\"o}lzel, Friedrich and Kroschinsky, Frank and Schetelig, Johannes and Bornh{\"a}user, Martin and Thiede, Christian and Middeke, Jan Moritz},
  title     = {Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia},
  series = {Cancers},
  volume    = {13},
  journal   = {Cancers},
  number    = {9},
  issn      = {2072-6694},
  doi       = {10.3390/cancers13092095},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-236735},
  year      = {2021},
  abstract  = {Acute myeloid leukemia (AML) is characterized by recurrent genetic events. The BCL6 corepressor (BCOR) and its homolog, the BCL6 corepressor-like 1 (BCORL1), have been reported to be rare but recurrent mutations in AML. Previously, smaller studies have reported conflicting results regarding impacts on outcomes. Here, we retrospectively analyzed a large cohort of 1529 patients with newly diagnosed and intensively treated AML. BCOR and BCORL1 mutations were found in 71 (4.6\%) and 53 patients (3.5\%), respectively. Frequently co-mutated genes were DNTM3A, TET2 and RUNX1. Mutated BCORL1 and loss-of-function mutations of BCOR were significantly more common in the ELN2017 intermediate-risk group. Patients harboring loss-of-function mutations of BCOR had a significantly reduced median event-free survival (HR = 1.464 (95\%-Confidence Interval (CI): 1.005-2.134), p = 0.047), relapse-free survival (HR = 1.904 (95\%-CI: 1.163-3.117), p = 0.01), and trend for reduced overall survival (HR = 1.495 (95\%-CI: 0.990-2.258), p = 0.056) in multivariable analysis. Our study establishes a novel role for loss-of-function mutations of BCOR regarding risk stratification in AML, which may influence treatment allocation.},
  language  = {en}
}
@article{StoerkBernhardtBoehmetal.2022,
  author    = {St{\"o}rk, Stefan and Bernhardt, Alexandra and B{\"o}hm, Michael and Brachmann, Johannes and Dagres, Nikolaos and Frantz, Stefan and Hindricks, Gerd and K{\"o}hler, Friedrich and Zeymer, Uwe and Rosenkranz, Stephan and Angermann, Christiane and Aßmus, Birgit},
  title     = {Pulmonary artery sensor system pressure monitoring to improve heart failure outcomes (PASSPORT-HF): rationale and design of the PASSPORT-HF multicenter randomized clinical trial},
  series = {Clinical Research in Cardiology},
  volume    = {111},
  journal   = {Clinical Research in Cardiology},
  number    = {11},
  doi       = {10.1007/s00392-022-01987-3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-324026},
  pages     = {1245-1255},
  year      = {2022},
  abstract  = {Background Remote monitoring of patients with New York Heart Association (NYHA) functional class III heart failure (HF) using daily transmission of pulmonary artery (PA) pressure values has shown a reduction in HF-related hospitalizations and improved quality of life in patients. Objectives PASSPORT-HF is a prospective, randomized, open, multicenter trial evaluating the effects of a hemodynamic-guided, HF nurse-led care approach using the CardioMEMS™ HF-System on clinical end points. Methods and results The PASSPORT-HF trial has been commissioned by the German Federal Joint Committee (G-BA) to ascertain the efficacy of PA pressure-guided remote care in the German health-care system. PASSPORT-HF includes adult HF patients in NYHA functional class III, who experienced an HF-related hospitalization within the last 12 months. Patients with reduced ejection fraction must be on stable guideline-directed pharmacotherapy. Patients will be randomized centrally 1:1 to implantation of a CardioMEMS™ sensor or control. All patients will receive post-discharge support facilitated by trained HF nurses providing structured telephone-based care. The trial will enroll 554 patients at about 50 study sites. The primary end point is a composite of the number of unplanned HF-related rehospitalizations or all-cause death after 12 months of follow-up, and all events will be adjudicated centrally. Secondary end points include device/system-related complications, components of the primary end point, days alive and out of hospital, disease-specific and generic health-related quality of life including their sub-scales, and laboratory parameters of organ damage and disease progression. Conclusions PASSPORT-HF will define the efficacy of implementing hemodynamic monitoring as a novel disease management tool in routine outpatient care. Trial registration ClinicalTrials.gov; NCT04398654, 13-MAY-2020.},
  language  = {en}
}